Interestingly, CB2-selective agonists were also found to reduce the tumor burden in vivo, inhibiting the proliferation and invasion of breast cancer cells into the intramedullary femoral cavity as well as the release of proinflammatory mediators69,71. Here, CNR2 is linked to breast cancer.